


Figure 1A




Figure 1B



A
VL1
-NH2
E or K Coil
B
-COOH
VH2
NH2- CH2-CH3 Domains -COOH
VL1
A
-NH2
E
VH2
VH2
B
VL2
D
-NH2
NH2- CH2-CH3 Domains -COOH
CH2-CH3 Domains -COOH
-COOH
VH2
E
CH2-CH3 Domains -COOH
K or E Coil
VL2
-NH2
D

Figure 1C




HEK 293 D375 + NK Cells (purified by positive selection) D56678 (LDH) E:T=5:1 24hr
Cytotoxicity (%)
35
30
25
20
15
10
5
0
10-1
100
101
102
103
104
Concentration (ng/ml)
Anti-HIV env (7B2) x Anti-CD16 (h3G8) Diabody
Anti-Fluorescein (4-4-20) x Anti-CD16 (h3G8) Diabody

Figure 2


HEK 293 D375 (5K/well) + NK Cells (purified by negative selection) D55386 (LDH) E:T=5:1 24hr



- Anti-HIV env (7B2) x Anti-CD16 (h3G8) Diabody
- Anti-HIV env (7B2) x Anti-CD3 (hAntibody 2) Diabody
- Anti-Fluorescein (4-4-20) x Anti-CD16 (h3G8) Diabody

Figure 3

HEK 293 D371 (5K/well) + NK Cells (purified by negative selection) D55386 (LDH) E:T=5:1 24h



Anti-HIV env (7B2) x Anti-CD16 (h3G8) Diabody

Anti-HIV env (7B2) x Anti-CD3 (hAntibody 2) Diabody

Anti-Fluorescein (4-4-20) x Anti-CD16 (h3G8) Diabody

Figure 4



-Tet (Induced)
Jurkat 522 FY (HxB2 gp160) (10K/well) + Pan T Cells D54670
(LDH) E:T=10:1 24h
Cytotoxicity (%)
20
15
10
5
0
-5
10-4
10-2
100
102
104
Concentration (ng/mL)
Anti-HIV gp120 (A32) x Anti-CD3 (hAntibody 2) Diabody
Anti-HIV env (7B2) x Anti-CD3 (hAntibody 2) Diabody
Anti-RSV F Protein (Palivizumab) x Anti-CD3 (hAntibody 2) Diabody

Figure 5



1μg/mL Dox (Induced) (CM244)
HEK 293 D375 (92Th023 gp140) + Pan T Cells D47239
(LDH) E:T=10:1 24h
Cytotoxicity (%)
30
20
10
0
10-6
10-4
10-2
100
102
104
Concentration (ng/mL)
Anti-HIV gp120 (A32) x Anti-CD3 (hAntibody 2) Diabody
Anti-HIV env (7B2) x Anti-CD3 (hAntibody 2) Diabody
Anti-HIV env (7B2) x Anti-Fluorescein (4-4-20) Diabody

Figure 6



1μg/mL Dox (Induced)
HEK 293 D371 (CM244 gp140) + Pan T Cells D47239
(LDH) E:T=10:1 24h
Cytotoxicity (%)
20
15
10
5
0
-5
10-6
10-4
10-2
100
102
104
Concentration (ng/mL)
Anti-HIV gp120 (A32) x Anti-CD3 (hAntibody 2) Diabody
Anti-HIV env (7B2) x Anti-CD3 (hAntibody 2) Diabody
Anti-HIV env (7B2) x Anti-Fluorescein (4-4-20) Diabody

Figure 7